Tebanicline

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Tebanicline (ABT-594, Ebanicline) acts as a partial agonist at neuronal nicotinic acetylcholine receptors, binding to both the α3β4 and the α4β2 subtypes.

Tebanicline (ABT-594, Ebanicline) acts as a partial agonist at neuronal nicotinic acetylcholine receptors, binding to both the α3β4 and the α4β2 subtypes. Tebanicline is an effective synthetic nicotinic (non-opioid) analgesic drug developed by Abbott. It was developed as a less toxic analog of the potent poison dart frog-derived compound epibatidine, which is some 200x stronger than morphine as an analgesic but produces extremely dangerous toxic side effects. Like epibatidine, Tebanicline showed potent analgesic activity against neuropathic pain in both animal and human trials, but with far less toxicity than its parent compound.

——

Cell Cycle/DNA Damage

PLK

nAChR

——

——

198283-73-7

198.65

C9H11ClN2O

98%

——

C1CN[C@H]1COc1cnc(cc1)Cl

——

(-20℃)

With Ice Pack

≥ 2 years